Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

FDA

From FDA - Page 13
Agency lays out 2018 plan to preserve legitimate pharmacy practices and protect patients; FDA also issues guidances for “essentially a copy” provisions and biologics products.
FDA Sets Compounding Policy Priorities Plan
Codeine Cough Syrup / Image: Alpharma
FDA Requires Stricter Labeling for Opioid Cough Medicine
FDA Commissioner Scott Gottlieb, MD, spoke about the Cures Act, citing progress on cancer drug approvals.
FDA Updates 21st Century Cures Act Implementation
Dr. Scott Gottlieb, FDA Commissioner / Image: Getty Images
FDA's Gottlieb on Promoting Generic Opioids to Curb Abuse
Dr. Scott Gottlieb, Commissioner of the Food and Drug Administration (FDA), testifies during a House Energy and Commerce Committee hearing concerning federal efforts to combat the opioid crisis, October 25, 2017 in Washington, DC.
FDA Addresses Opioids, Hurricane Relief, Regenerative Meds
Medical device firms need to consider their data strategy and ensure the right structure is in place for establishing clean UDIs in order to contribute to patient safety.
Focus on Data Quality to Prepare for Class III UDI Implementation
From blisters to dose tracking, FDA identifies packaging strategies as a key effort in fighting the opioid epidemic.
FDA: Packaging Provides ‘Meaningful Impact’ in Opioid Crisis
FDA Commissioner Scott Gottlieb, MD
FDA addresses medical device manufacturing recovery in Puerto Rico
FDA Commissioner Scott Gottlieb, MD
FDA Addresses Medical Device Manufacturing Recovery in Puerto Rico
Cyberhacked / Image: FiercePharma
New Bill Seeks Better Cybersecurity for Medical Devices
Cigarettes / Image: Getty
FDA Reconsiders Cigarette Packaging
FDA issues guidance to advance novel treatment therapies that often require advanced manufacturing technology. Could it help lower pharma manufacturing costs?
Reaching an ‘Inflection Point’ in Pharmaceutical Manufacturing
Previous Page
Page 13 of 15
Next Page